This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Summary statistics from individual studies were used.
Number of primary studies included
At least 23 studies were included in the review.
Methods of combining primary studies
The narrative method was used to combine primary studies.
Investigation of differences between primary studies
Results of the review
The results of the review were as follows:
The efficacy of prophylaxis was taken to be 90%.
The risk of a severe, non-fatal reaction to prophylaxis was 0.01%.
The risk of a fatal reaction to prophylaxis was 0.002%.
Life expectancy was 17.84 years for a 60-year-old man.
The risk of bacterial arthritis related mortality was 20% (95% CI: 10 -30) and the risk of major loss of joint function was 40% (95% CI: 25 -55).
An 'impaired' state carried a utility of 0.75.
Severe non-fatal side effects of antibiotics caused a loss of 4 quality adjusted life days (QALDs).
The data formed the principal input parameters for the decision tree.
Measure of benefits used in the economic analysis
QALDs were used as the measure of benefit. Utility values were derived using the EuroQol questionnaire. Patients' values were used to value health states.
Direct costs
Direct costs were, appropriately, not discounted (time horizon = 1 year). Quantities and costs were reported separately. Direct costs reflected all medical costs for the first year after diagnosis of bacterial arthritis (costs of hospital stay and medical treatment, cost of physiotherapy, and cost of stay in a rehabilitation clinic or nursing home). The quantity/cost boundary adopted was that of the health service. The estimation of quantities and costs was based on actual data. Costs and quantities were taken from a survey of 37 patients with bacterial arthritis and a published source. The price year 
Statistical analysis of costs
No statistical analysis was carried out.
Indirect Costs
Indirect costs were not included.
Currency
Dutch guilders (Dfl) with Dfl 1 = $ 0.60.
Sensitivity analysis
Sensitivity analyses to assess the impact of assumptions were conducted on all model parameters. The sensitivity analyses addressed three questions:
for which risk situation is there certainty about the relative effectiveness of prophylaxis?
which factors in the model have a relevant effect on the cost-effectiveness estimates; and
what is the effect of age and sex on the cost-effectiveness estimates?
Estimated benefits used in the economic analysis
The risk of bacterial arthritis was 0.13% after a dermal infection (95% CI: 0.05 -0.21), 0.02% after a low risk infection (95% CI: 0.0004 -0.04), and 0.005% after an invasive medical procedure (95% CI: 0 -0.03).
The patient's susceptibility to bacterial arthritis was related to the presence of a knee or hip prosthesis (coefficient = 1.9; 95% CI: 1.2 -2.6), a diagnosis of rheumatoid arthritis (coefficient = 1.4; 95% CI: 0.6 -2.1), comorbidity (coefficient = 1.3; 95% CI: 0.4 -2.2), and age of 80 and over (coefficient = 1.1; 95% CI: 0.3 -2.0).
Prophylaxis was more effective for dermal infections, infections of the urinary tract or respiratory tract if the patient's susceptibility was increased, and invasive medical procedures only if the patient's susceptibility was moderate or high.
The benefits of prophylaxis ranged from 0.4 to 35 QALDs for dermal infections, from -0.07 to 3.39 QALDs for infections of the urinary tract or respiratory tract, and from -0.11 to 0.91 for an invasive medical procedure.
Cost results
The difference in costs (prophylaxis minus no prophylaxis) ranged from $56 to $-237 for dermal infections, from $59 to $-31 for infections of the urinary tract or respiratory tract, and from $12.10 to $3.20 for an invasive medical procedure.
Synthesis of costs and benefits
The marginal cost-effectiveness ranged from $52,000 to $3,300 per quality adjusted life year (QALY) for dermal infections. For patients with high susceptibility, prophylaxis dominated (more effective and less costly).
The marginal cost-effectiveness ranged from $550,000 to $3,300 per QALY for infections of the urinary tract or respiratory tract. For patients with low susceptibility, no prophylaxis dominated.
The marginal cost-effectiveness ranged from $1,000,000 to $1,300 per QALY for an invasive medical procedure. For patients with low susceptibility, no prophylaxis dominated.
